UBS Group AG boosted its stake in shares of ViewRay, Inc. (NASDAQ:VRAY) by 447.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,479 shares of the company’s stock after buying an additional 18,375 shares during the period. UBS Group AG’s holdings in ViewRay were worth $192,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. FIL Ltd purchased a new position in shares of ViewRay during the first quarter valued at $6,348,000. Next Century Growth Investors LLC purchased a new position in shares of ViewRay during the first quarter valued at $2,987,000. EAM Investors LLC purchased a new position in shares of ViewRay during the first quarter valued at $1,612,000. Geode Capital Management LLC raised its position in shares of ViewRay by 158.7% in the first quarter. Geode Capital Management LLC now owns 149,463 shares of the company’s stock valued at $1,271,000 after buying an additional 91,694 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in shares of ViewRay during the first quarter valued at $669,000. 48.69% of the stock is owned by institutional investors and hedge funds.
ViewRay, Inc. (NASDAQ:VRAY) opened at 5.30 on Friday. ViewRay, Inc. has a 12-month low of $2.64 and a 12-month high of $10.39. The company’s market capitalization is $312.74 million. The stock has a 50 day moving average price of $5.65 and a 200-day moving average price of $6.25.
WARNING: “UBS Group AG Has $192,000 Stake in ViewRay, Inc. (VRAY)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/viewray-inc-vray-shares-bought-by-ubs-group-ag-updated.html.
VRAY has been the subject of several research reports. Aegis reissued a “buy” rating and set a $11.00 price objective on shares of ViewRay in a report on Tuesday, May 16th. ValuEngine lowered ViewRay from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Cantor Fitzgerald initiated coverage on ViewRay in a report on Thursday, June 29th. They set an “overweight” rating and a $10.00 price objective for the company. Northland Securities reissued a “buy” rating and set a $7.00 price objective on shares of ViewRay in a report on Tuesday, May 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of ViewRay in a report on Wednesday, May 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $9.50.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
What are top analysts saying about ViewRay Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ViewRay Inc. and related companies.